|
|
|
|
As InspiroGene prepares to launch the 2025 Cell and Gene Therapy Report, now is your chance to revisit foundational insights from the 2024 edition. This resource features pipeline data, oncologist survey results, a map of qualified treatment centers, and expert-driven strategies for increasing patient access. Stay ahead of what’s next. Sign up below to be among the first to receive the 2025 report.
|
|
|
|
|
In part one of this article series, Joe DePinto, Head of Cell, Gene and Advanced Therapies at McKesson, covers five best practices for companies preparing to bring their first CGT product to market, from early planning to infrastructure readiness.
|
|
|
|
|
CGT commercial success takes more than innovation – it takes strategy. In part two of this series on commercializing your first CGT, Joe DePinto outlines the components of an effective market access plan to ensure life-changing therapies reach patients who need them most.
|
|
|
|
|
|
|
|
|
|
Purpose-Built Just For CGT
|
Discover InspiroGene’s state-of-the-art cold chain facility, integrating advanced cryogenic storage, on-site specialty pharmacy, and streamlined distribution to eliminate friction across the supply chain and empower stakeholders to deliver life-changing therapies with confidence and efficiency.
|
|
• Request Information
|
|
|
|
|
|
|
|
|
|
|
|
